AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14504627
Drug: Low group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low group (one face-to-face individual counselling session, then monthly telephone contacts for 1 year)
Trial: 8899756
Drug: Heparinized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparinized saline flush (2.5 ml, 100 U/ml)
Trial: 8899756
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline flush (5 ml)
Trial: 6846212
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal insulin responses)
Trial: 30540689
Drug: Control (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (intravenous thrombolysis with urokinase)
Trial: 30184455
Drug: Baloxavir (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baloxavir (40 or 80 mg)
Trial: 24999213
Drug: Buscopan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan (20 mg intravenously)
Trial: 22173517
Drug: Selective digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective digestive decontamination (SDD) with oral gentamicin (80 mg 4 times per day) and oral polymyxin E gel (0.5 g 4 times per day) for 7 days
Trial: 22173517
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral placebo gel and 2 placebo oral solutions 4 times per day for 7 days)
Trial: 10352387
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + transdermal estrogen
Trial: 8687263
Drug: Computer reminders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer reminders printed on daily rounds reports about preventive care for which their patients were eligible.
Trial: 28393258
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen treatment (usual care)
Trial: 25418079
Drug: Biotène(®) mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotène(®) mouthwash Oral Rinse
Trial: 25117615
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 250 mg
Trial: 25117615
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 500 mg
Trial: 22526411
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 750 mg
Trial: 22526411
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 1000 mg
Trial: 11787914
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of misoprostol (400 microg initial dose, followed by 200 microg two hours later and then four-hourly 200 microg doses)
Trial: 11787914
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of misoprostol (400 microg initial dose, followed by 200 microg two hours later and then four-hourly 200 microg doses)
Trial: 9422305
Drug: Ketoprofen 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 1.4 mg x kg(‐1)
Trial: 9422305
Drug: Ketorolac 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.4 mg x kg(‐1)
Trial: 9422305
Drug: Diclofenac 1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 1.1 mg x kg(‐1)
Trial: 25751000
Drug: Collaborative &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative & Proactive Solutions (CPS)
Trial: 31376090
Drug: Rivaroxaban and
RxNorm normalized name: rivaroxaban and acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban and Warfarin
Trial: 20544158
Drug: Sham intramuscular
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham intramuscular dry needle puncture (Control)
Trial: 18793221
Drug: Hemofiltration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemofiltration with constant flow of 300 mL/m²/min and filtrate volume of 3000 mL
Trial: 12787969
Drug: CEE (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE (conjugated equine estrogens 0.625 mg)
Trial: 16680067
Drug: CEE/MPA (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg)
Trial: 12787969
Drug: E(2)/NETA (17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2)/NETA (17beta‐estradiol 2 mg plus norethisterone acetate 1 mg)
Trial: 12787969
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (women who declined or did not qualify for treatment)
Trial: 10951147
Drug: Cyclosporin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (4 mg kg‐1 daily for 4 weeks)
Trial: 8838437
Drug: Sustained-release tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tramadol (100 mg)
Trial: 8838437
Drug: Sustained-release tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tramadol (200 mg)
Trial: 8838437
Drug: Sustained-release tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tramadol (100 mg and 200 mg)
Trial: 8838437
Drug: Sustained-release tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release tramadol
Trial: 1468244
Drug: CR dihydrocodeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR dihydrocodeine (60 mg) tablets (1 tablet twice daily to 2 tablets daily)
Trial: 1468244
Drug: Combination dextropropoxyphene
RxNorm normalized name: dextropropoxyphene
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination dextropropoxyphene (32.5 mg)/paracetamol (325 mg) tablets (2 tablets 3‐times daily to 2 tablets 4‐times daily)
Trial: 28012819
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR (6 μg)
Trial: 28012819
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR (10 μg)
Trial: 28012819
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR (15 μg)
Trial: 28012819
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR (20 μg)
Trial: 28012819
Drug: Topical bimatoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bimatoprost 0.03%
Trial: 28012819
Drug: Topical bimatoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bimatoprost
Trial: 26497960
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (DE) exposure for 2 hours with a particulate matter concentration of 300 μg/m(3)
Trial: 19528562
Drug: Red yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red yeast rice, 1800 mg twice daily for 24 weeks
Trial: 19528562
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 24 weeks
Trial: 17530404
Drug: Random Controlled
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random Controlled Trial (RCT) design for evaluating sexual offender treatment
Trial: 17530404
Drug: Alternative strategies
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative strategies for evaluating treatment
Trial: 17151968
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK solution (500 ml of 30% dextrose solution, containing 100 IU insulin and 80 mEq of potassium, at a rate of 1 ml x kg (‐1) x h (‐1))
Trial: 14615106
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis extract (n=211)
Trial: 22427020
Drug: Caffeine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1 mg/kg)
Trial: 30643069
Drug: Manipulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation therapy
Trial: 19018915
Drug: TTT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TTT intervention (educational train-the-trainer course plus pharmacotherapy feedback)
Trial: 15675981
Drug: rHuEPO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO therapy
Trial: 8602180
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of beta carotene per day and 25,000 IU of retinol (vitamin A) per day
Trial: 1943090
Drug: rHGH (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHGH (0.2 mg/kg.d)
Trial: 30702971
Drug: Celecoxib with
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib with neoadjuvant chemotherapy
Trial: 30702971
Drug: Celecoxib with
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib with neoadjuvant chemotherapy in PTGS2-low group (n = 100)
Trial: 28476567
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily insulin dose per kilogram
Trial: 23645323
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (34% of children)
Trial: 3090583
Drug: O +
RxNorm normalized name: Acti-Lipo + Pyridoxine Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O + O (no drugs)
Trial: 21890335
Drug: Ciclesonide/Formoterol 320/9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide/Formoterol 320/9 μg bid (CIC/F)
Trial: 21890335
Drug: Fluticasone Propionate/Salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone Propionate/Salmeterol 250/50 μg bid (FP/S)
Trial: 18541174
Drug: Highly discounted
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly discounted vaccine from local health departments
Trial: 11086369
Drug: Androstenedione 100
RxNorm normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androstenedione 100 mg/d for 7 days
Trial: 11086369
Drug: Androstenedione 300
RxNorm normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androstenedione 300 mg/d for 7 days
Trial: 1552034
Drug: Buspirone (57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (57 +/- 7 mg/day)
Trial: 2863089
Drug: Bromazepam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (3 to 9 mg per day)
Trial: 2863089
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 to 3 mg per day)
Trial: 18653575
Drug: Other protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other protease inhibitors (Control)
Trial: 16771937
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PPI and H. pylori testing
Trial: 16771937
Drug: Empirical antisecretory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antisecretory therapy (PPI)
Trial: 2166209
Drug: CY 216
RxNorm normalized name: Cys
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CY 216 (once daily)
Trial: 30133164
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy for 12 weeks
Trial: 4811950
Drug: Social therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social therapy for 12 weeks
Trial: 28187400
Drug: Escitalopram plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram plus placebo (SSRI monotherapy)
Trial: 28187400
Drug: Bupropion plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion plus escitalopram combination (bupropion-SSRI combination)
Trial: 22527138
Drug: Alfacalcidol +
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol + 500 mg calcium (group A)
Trial: 22527138
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D + 1000 mg calcium (group B)
Trial: 19222323
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment over 17 weeks
Trial: 14648310
Drug: Double-lumen totally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-lumen totally implantable subcutaneous port system (PORT)
Trial: 11238504
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL isotonic saline i.v. at 0 min)
Trial: 9669256
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (10 mg/min)
Trial: 8310993
Drug: Beta-carotene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (30 mg)
Trial: 8310993
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (300 mg)
Trial: 3047335
Drug: Vincristine, cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine, cyclophosphamide, and doxorubicin (VCA) for six monthly cycles
Trial: 29901736
Drug: LNS-LNS (Lipid-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNS-LNS (Lipid-Based Nutrient Supplements for women and children)
Trial: 20925074
Drug: Orally dissolving
RxNorm normalized name: MUCOTROL Sugar-free Orally Dissolving Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally dissolving carbidopa/levodopa (OD C/L)
Trial: 20925074
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral carbidopa/levodopa
Trial: 11738543
Drug: Both sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sertraline and desipramine (responders)
Trial: 11738543
Drug: Both sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sertraline and desipramine (non-responders)
Trial: 11738543
Drug: Clinical change
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical change (not medication)
Trial: 28089184
Drug: Bone wax
RxNorm normalized name: bone wax applicator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone wax (2.5 g applied onto uncovered bone)
Trial: 26177518
Drug: IdeS (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IdeS (intravenous single ascending doses)
Trial: 26177518
Drug: IdeS (0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IdeS (0.24 mg/kg)
Trial: 23261172
Drug: Lisinopril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (40 mg/day) and a regular sodium diet (194 ± 49 mmol Na+/day)
Trial: 23261172
Drug: Lisinopril plus
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril plus valsartan (320 mg/day) and a low sodium diet (102 ± 52 mmol Na+/day)
Trial: 23261172
Drug: Maximal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal treatment
Trial: 17582922
Drug: Zonisamide plus
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide plus previous treatment
Trial: 17582922
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus previous treatment
Trial: 15044114
Drug: MTHFR genotypes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTHFR genotypes (CC or CT)
Trial: 11569889
Drug: Dolasetron 100
RxNorm normalized name: dolasetron 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 100 mg daily
Trial: 11569889
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ondansetron or granisetron)
Trial: 9814477
Drug: SB (steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB (steroid and LH free) after R‐FSH administration
Trial: 934535
Drug: Reserpine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserpine (1.5 mg/1.7 m2 surface) administered as a single i.m. injection
Trial: 934535
Drug: Prolonged reserpine
RxNorm normalized name: Reserpine
DrugBank: Reserpine (DB00206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged reserpine medication (0.2 mg reserpine 3 times a week for 6 weeks)
Trial: 934535
Drug: Prolonged reserpine
RxNorm normalized name: Reserpine
DrugBank: Reserpine (DB00206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged reserpine medication
Trial: 28525788
Drug: Intervention for
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention for stimulant abuse/dependence
Trial: 17294169
Drug: 3-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day course of antibiotics and catheter replacement 4 hours after first antibiotic administration
Trial: 17294169
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (no antibiotics, no catheter replacement)
Trial: 17294169
Drug: 3-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day course of antibiotics and catheter replacement
Trial: 15153170
Drug: Orlistat (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (3 x 120 mg/day)
Trial: 2048868
Drug: Ciprofloxacin, 500
RxNorm normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg orally every 12 hours
Trial: 31094774
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg amisulpride
Trial: 30488222
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amisulpride
Trial: 23152584
Drug: Immunohistochemical assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemical assay of sarcolemmal chloride channel abundance using 2 different ClC1‐specific antibodies
Trial: 20551460
Drug: Azathioprine 2.0-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 2.0-2.5 mg/kg/day
Trial: 16371154
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg single dose in second trimester)
Trial: 12460041
Drug: Progressive resisted
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resisted isotonic quadriceps and hamstrings exercise and training on a cycle ergometer three times weekly for 12 weeks
Trial: 10597763
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of phytonadione IV
Trial: 10597763
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of phytonadione SC
Trial: 1423955
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (20 mg followed by 25 mg bolus doses and 10 and 15 mg/hr infusion for 24 hours)
Trial: 31444189
Drug: Lifestyle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle treatment (information emphasising the disease's lifestyle causes)
Trial: 24499772
Drug: Moderate Fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Fat with 10 g of ground flaxseed added daily (n=49)
Trial: 24499772
Drug: Moderate Fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Fat without 10 g of ground flaxseed added daily (n=49)
Trial: 20854868
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) applied over the dorsolateral prefrontal cortex using a 2 mA-current for 20 min, twice-daily, for 5 consecutive days.
Trial: 20155617
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carotenoids and myo‐inositol
Trial: 17524594
Drug: High marking
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High marking of the argumentative orientation and daily estimates
Trial: 15212190
Drug: Tulobuterol TTS
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol TTS (Hokunalin Tape) with inhalational steroids